Physician profile
Charles Whitehead
NPI 1962763466
$3,204.57
in general payments reported to CMS, 2019-2025
25 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,643 · 2020: $1,345 · 2021: $82.35 · 2022: $23.18 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $110.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $565.70 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $506.83 | 2019-2020 | |
| Amarin Pharma, INC. | $485.38 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $199.34 | 2019-2020 | |
| Lilly USA, LLC | $171.78 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $144.13 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.09 | 2019-2020 | |
| Abbott Laboratories | $110.76 | 2025 | Assurity |
| Astellas Pharma US INC | $107.94 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $97.32 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $94.54 | 2019 | |
| Gilead Sciences, INC. | $91.90 | 2019-2020 | |
| Glaxosmithkline, LLC. | $87.00 | 2019-2020 | |
| Pfizer INC. | $61.81 | 2019-2020 | |
| Allergan, INC. | $54.31 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $44.74 | 2019 | |
| Abbvie INC. | $40.97 | 2019-2022 | |
| Genentech USA, INC. | $39.80 | 2019-2020 | |
| Sanofi Pasteur INC. | $35.31 | 2019 | |
| Amgen INC. | $30.93 | 2019 | |
| Cranial Technologies, INC | $24.15 | 2019 | |
| Pacira Therapeutics, INC. | $23.89 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.35 | 2019 | |
| Dynavax Technologies Corporation | $15.92 | 2020 | |
| Evoke Pharma, INC. | $14.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Whitehead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.